Novartis To Buy Breast Cancer Therapy For Up To $3B

Novartis AG said Friday that it will acquire a breast cancer drug from U.S. developer Synnovation Therapeutics in a deal worth up to $3 billion as it seeks to strengthen its...

Already a subscriber? Click here to view full article